Immune signatures to affect overall survival (OS) and response to bevacizumab (Bev) or cetuximab (Cet) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)
- Citation:
- J Clin Oncol vol 39 (15_suppl) 3515
- Meeting Instance:
- ASCO 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3632
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U24CA196171
- Corr. Author:
- Authors:
- Federico Innocenti Akram Yazdani Xueping Qu Fang-Shu Ou Scott Van Buren Omar Kabbarah Charles David Blanke Alan P. Venook Heinz-Josef Lenz Benjamin Garrett Vincent
- Networks:
- Study
- CALGB-80405
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: